Noven's Stavzor receives US nod for three indications
This article was originally published in Scrip
Executive Summary
Noven has received approval from the US FDA for its bipolar disorder drug Stavzor (valproic acid delayed release capsules) for the treatment of three separate indications, and will be launched this month.
You may also be interested in...
Cerimon receives positive Phase II data on diclofenac patch
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Lilly's Alimta among SMC's September recommendations
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.